Drugs / DF1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04143711 | Nov 2019 → Dec 2025 | cancer | Dragonfly Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-06-05 | Dragonfly Therapeutics | Results Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results dragonflytx.com ↗
DF1001 pharmacodynamic activity was demonstrated in 67% (28/42) of paired biopsies in monotherapy. |
| 2021-11-09 | Dragonfly Therapeutics | Regulatory Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer dragonflytx.com ↗
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that its wholly-owned HER2-targeted NK cell engager therapy, DF1001, has been granted Orphan Drug Designation (ODD) in the US for treatment of esophageal cancer. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-02-15 | Dragonfly Therapeutics | Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications dragonflytx.com ↗ |
| 2023-06-05 | Dragonfly Therapeutics | Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results dragonflytx.com ↗ |
| 2022-12-05 | Dragonfly Therapeutics | Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001 dragonflytx.com ↗ |
| 2021-11-09 | Dragonfly Therapeutics | Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer dragonflytx.com ↗ |
| 2019-11-12 | Dragonfly Therapeutics | Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors dragonflytx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DF1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04143711 ↗ |